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OBJECTIVES: To compare the budget impact in the main Public Health Institution 
in Mexico due to the use of MF59-adjuvanted vaccine (MF59), split vaccine (SPL) 
and a No Vaccination Program Alternative (NOVA) in Mexican elderly population. 
METHODS: A budget impact analysis considering a public health institution perspec-
tive was performed. The expenses of the Mexican Health Care System due to a vacci-
nation program (vaccines, vaccination program, medical visits, treatment of inﬂuenza 
and inﬂuenza related complications, hospitalization and intensive care unit cost) were 
simulated with MF59 or SPL versus NOVA in elderly population affected by an 
inﬂuenza pandemic. A case scenario of high incidence inﬂuenza (5% of population) 
with three sub-scenarios was designed: a) 20%, b) 30%, and c) 50% of patients 
developing complications related to inﬂuenza. A systematic literature review was 
designed in order to include the most recent information about vaccines effectiveness 
measured as the ability of provide seroprotection against Inﬂuenza A/H1N1 strain and 
pandemic historical inﬂuenza incidences recommended by World Health Organiza-
tion. Use of resources and cost matrixes were designed with the most recent data of 
main Public Health Institution in Mexico, which attends about ﬁfty percent of the 
total population in Mexico. RESULTS: The cost of treatment of inﬂuenza and com-
plications related to inﬂuenza were estimated in US$38.84 and US$5,052.06, res-
pectively. Simulating prevention of inﬂuenza pandemic affecting 5% of Mexican 
elderly population results in less expenses for Public Health Institutions when 
MF59 is used in vaccination program compared to SPL and NOVA without varying 
the proportion of patients getting complications related to inﬂuenza (20%: MF59-
US$69,833,474.83; SPL-US$84,692,366.64; NOVA-US$236,082,644.63. 30%: 
MF59-US$84,610,768.22; SPL-US$117,657,098.05; NOVA-US$349,754,132.23. 50%: 
MF59-US$113,903,164.91; SPL-US$183,586,560.86; NOVA-US$577,097,107.44). 
CONCLUSIONS: Using an MF59-adjuvanted vaccine as a preventive alternative in 
an Inﬂuenza Pandemic affecting elderly population in Mexico, represents important 
savings for Mexican Public Health Institutions compared to SPL and NOVA.
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OBJECTIVES: A budget impact model (BIM) was developed to estimate the economic 
impact of intraconazole in prophylaxis of invasive fungal infections (IFI) in patients 
with neutropenia in Spain. METHODS: A BIM was developed using published data 
for disease prevalence, population growth, pharmaceutical ex-factory prices, health 
care resource consumption and market shares forecasting for Spain. This study was 
developed under the perspective of the health care system and time horizon considered 
was 5 years with an annual discount rate of 3%. According to a panel of clinical 
experts, drugs considered in this study were all different “azoles” currently used in 
prophylaxis in Spain regardless whether they have been authorized for this purpose 
or not. These are the following ones: itraconazole, posaconazole, ﬂuconazole and 
voriconazole. This model estimated the cost of this disease for the Spanish health care 
system with and without the partial replacement (from 5% to 15%) of posaconazale 
by itraconazole. All costs were referred to year 2009. RESULTS: According to ofﬁcial 
statistic, target population with hematologic cancers in prophylaxis of IFI in Spain 
would be around 70,000 patients in the ﬁrst year, arriving at 75,000 in the 5th year. 
Direct medical costs for the next 5 years were estimated at a1424 million before the 
replacement of posaconazole by itraconazole. Costs were estimated at a1423 million 
whether this replacement would take place. CONCLUSIONS: The replacement of 
posaconazale by itraconazole in a very low percentage (from 5% to 15%) would 
represent a savings of a830,000 for the Spanish health care system in the next 5 
years.
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OBJECTIVES: To analyze the budget impact of two newly registered for Bulgaria 
antiretroviral medicines tenofovir and emtricitabine for treatment of HIV infection. 
The point of view is that of health care system and time horizon is one year. 
METHODS: Budget impact model was created for antiretroviral medicinal therapies 
for ﬁrst and second line treatment. Two scenarios were analyzed for highly active 
antiretroviral therapy (HAART) including 12 medicines combinations for ﬁrst line and 
7 combinations for second line therapy. Health care resources included in the model 
are medicines, physician consultation ﬁrst and 11 follow up attendances, 12 clinical, 
3 virology and 6 immunology tests. In the model was varied the cost of the medicines 
therapy and number of patients. RESULTS: Untill June 2009 in Bulgaria are registered 
991 HIV positive patients and near 230 of them are on highly active antiretroviral 
therapy (HAART)—ﬁrst or second line depending on their virology status. Preliminary 
results from the budget impact model show that in the ﬁrst scenario (ﬁrst line therapy) 
the combination tenofovir—emtricitabine—efavirenz is cost saving to the health care 
system compared to three of the most effective HAART regimens: AZT/3TC- LPV/r, 
3TC/ABC- SQV and TDF-3TC-EFV and saves 141 981,46 Euro, 83461,53 Euro and 
a2445.99, respectively for one year. The second scenario (second line therapy) is 
indicated only for certain patients according to their virology status. In this scenario 
the regimen TDF-FTC-EFV is cost saving to the health care system in comparison with 
TDF-3TC-EFV and saves a2445.99. CONCLUSIONS: TDF-FTC-EFV is cost saving 
for the health care system compared to three of the most effective regimens in Bulgaria. 
The combination is much appropriate as ﬁrst line HAART.
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OBJECTIVES: Three candins had been approved for the treatment of invasive candi-
diasis (IC). Different drugs are associated with different needs for dose adjustment 
which might affect the total cost. The aim of this study was to estimate the budget 
impact of caspofungin, micafungin and anidulafungin in the treatment of 100 patients 
with invasive candidiasis from the perspective of the Spanish hospital pharmacy 
setting. METHODS: Possible scenarios varying percentage of doses adjustment 
required were also considered to assess the global impact on costs. Prices for each 
presentation were obtained from the Spanish database “portalfarma”, expressed in 
a2008. Only drug acquisition costs were considered into the analysis. Total cost for 
the three candins was ﬁnally displayed. RESULTS: Cost per episode associated with 
the use of anidulafungin remained constant at a6000. When considering caspofungin, 
cost-per-episode varies from a4665 to a7991 depending on the patient’s weight and 
hepatic dysfunction. Finally micafungin total cost-per-episode was estimated at a6,000 
when low doses where required while higher doses based on inadequate respond had 
a cost of a10,714 per IC episode. Total cost based on a hypothetic cohort of 100 
patients with IC treated with anidulafungin would be of a600,000, while the cost of 
caspofungin and micafungin on the base case will be a637,084 and a632,998, respec-
tively, depending on dose adjustment required. CONCLUSIONS: Patients treated with 
Anidulafungin did not required dose adjustment unlike caspofungin and micafungin. 
The use of anidulafungin in the treatment of adult non-neutropenic patients with 
invasive candidiasis is a cost saving treatment option that allows a better control of 
antifungal budget based on a lower total cost per episode, from the pharmacy depart-
ment perspective in Spain.
PIN13
BUDGET IMPACT MODEL: LEVOFLOXACIN VS STANDARD THERAPIES 
IN THE TREATMENT OF INPATIENT CAP
Pitrelli A1, Bamﬁ F1, Pippo L2
1GlaxoSmithKline Spa, Verona, Italy, 2GlaxoSmithKline Verona -Italy, Verona, Italy
OBJECTIVES: To develop a Budget Impact Model (BIM) to estimate the ﬁnancial 
consequences of the use of levoﬂoxacin for the treatment of community-acquired 
pneumonia (CAP) in Italian Hospitals to support health decision makers. METHODS: 
We developed a BIM for levoﬂoxacin that compares current treatments for CAP, their 
efﬁcacy and safety and the resource use and costs as apply to the population of interest. 
Several dimensions were considered: drug consumption, frequency and days of treat-
ment, health care professional costs, disposable (material), hospitalization costs and 
need of a second line treatment. Different scenarios in antibiotic treatment of CAP 
were included for comparison, such as i.v. therapy or switch therapy and levoxacin 
is compared to current alternative in monotherapy and in combination therapy. 
RESULTS: CAP is an infection still associated to considerable rates of morbidity and 
mortality and with important consequences from the social and economic perpspec-
tive. In Italy the annual incidence of hospitalization due to CAP is about 3 cases every 
1000 habitants, with rather high mortality rates: from 15/100.000 cases of the 
national mean to 70/100.000 cases for subjects older than 65 years. More than 90% 
of CAP costs are associated to hospitalizations (500 million euro. The model we 
developed results in an interactive tool that allows users (payers) to understand the 
relation between the characteristics of their scenario and the possible budget conse-
quences of the different treatment choices and informs them about the most affordable 
option among current treatments for CAP (including levoﬂoxacin) according to the 
features of their own scenario CONCLUSIONS: BIMs are primarily intended to     
inform health care decision makers, especially those who are responsible for national, 
regional, or local health care budgets. For this reason methodology and results were 
reviewed in an external engagement with payers to validate the model in a real 
scenario.
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OBJECTIVES: Bichat-Claude Bernard hospital (BCB) is one of the reference centers 
in HIV care in Paris (France) and has established procedures for post-exposure pro-
phylaxis (PEP). Only patients at high risk of contamination received antiretroviral 
(ARV) treatment. The aim of this study was to describe the use of PEP (occupational 
